Close

News

Abbott Confirms Long-Term Commitment to HIV Care

Abbott plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. The company is currently investigating a new powder formulation of Norvir as well...

Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers

Novartis has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza. Novartis plans...

XGEVA® (Denosumab) Granted Marketing Authorization in the European Union

Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with...

Roche provides update from FDA hearing on Avastin for metastatic breast cancer

Roche  announced that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin® (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative...

Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions

John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions. Lechleiter participated in the American Council on Germany's conference on "The...

Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses

Pfizer Inc. (NYSE: PFE) is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The...

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement

Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read